{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:05:29Z","timestamp":1767139529905,"version":"build-2238731810"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myelodysplastic syndromes (MDS) are hematopoietic stem cell malignancies associated with an erythroid maturation defect, resulting in anemia. Treatments for MDS include erythropoiesis-stimulating agents (ESAs). The identification of prognostic markers is important to help predict response and improve outcomes. Various scoring systems have been developed to help predict response to ESAs. Despite limitations in its assessment, serum erythropoietin (sEPO) level is an important predictor of hematologic response to ESAs in patients with lower-risk MDS. Numerous studies have reported significantly lower sEPO levels among responders versus non-responders. Furthermore, treatment response is significantly more likely among those with sEPO levels below versus those above various cutoffs. Other prognostic indicators for response to ESAs include lower transfusion requirement, fewer bone marrow blasts, higher hemoglobin, lower serum ferritin, lower-risk MDS, and more normal cytogenetics. Studies of other MDS therapies (e.g., lenalidomide and luspatercept) have also reported that lower sEPO levels are indicative of hematologic response. In addition, lower sEPO levels (up to 500 IU\/L) have been included in treatment algorithms for patients with lower-risk MDS to define whether ESAs are indicated. Lower sEPO levels are predictive of hematologic response\u2014particularly to ESAs. Further, clinical trials should use sEPO thresholds to ensure more homogeneous cohorts.<\/jats:p>","DOI":"10.1007\/s00277-019-03799-4","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T10:56:06Z","timestamp":1572432966000},"page":"7-19","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0514-5789","authenticated-orcid":false,"given":"Sophie","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charikleia","family":"Kelaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Casadevall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"3799_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ijc.27896","volume":"133","author":"J Li","year":"2013","unstructured":"Li J (2013) Myelodysplastic syndrome hematopoietic stem cell. (2013). Int J Cancer 133:525\u2013533","journal-title":"Int J Cancer"},{"key":"3799_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3343\/alm.2017.37.6.465","volume":"37","author":"G Zini","year":"2017","unstructured":"Zini G (2017) Diagnostics and prognostication of myelodysplastic syndromes. Ann Lab Med 37:465\u2013474","journal-title":"Ann Lab Med"},{"key":"3799_CR3","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292\u20132302","journal-title":"Blood"},{"key":"3799_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405","journal-title":"Blood"},{"key":"3799_CR5","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079\u20132088","journal-title":"Blood"},{"key":"3799_CR6","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","volume":"25","author":"L Malcovati","year":"2007","unstructured":"Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503\u20133510","journal-title":"J Clin Oncol"},{"key":"3799_CR7","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilst\u00f6cker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454\u20132465","journal-title":"Blood"},{"key":"3799_CR8","unstructured":"Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O\u2019Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C (2019) Myelodysplastic syndromes; referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Myelodysplastic Syndromes V2.2019 \u00a9 National Comprehensive Cancer Network, Inc, 2019. All rights reserved. Accessed May 8, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org . NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"3799_CR9","first-page":"432","volume":"143","author":"MP Carnot","year":"1906","unstructured":"Carnot MP, Deflandre C (1906a) Sur l\u2019activit\u00e9 h\u00e9mopoi\u00e9tique des diff\u00e9rents organes au cours de la r\u00e9g\u00e9n\u00e9ration du sang. C R Acad Sci Paris 143:432\u2013435","journal-title":"C R Acad Sci Paris"},{"key":"3799_CR10","first-page":"384","volume":"143","author":"P Carnot","year":"1906","unstructured":"Carnot P, Deflandre C (1906b) Sur l\u2019activit\u00e9 h\u00e9mopoi\u00e9tique du s\u00e9rum au cours de la r\u00e9g\u00e9n\u00e9ration du sang. C R Acad Sci Paris 143:384\u2013386","journal-title":"C R Acad Sci Paris"},{"key":"3799_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1748-1716.1948.tb00535.x","volume":"16","author":"E Bonsdorff","year":"1948","unstructured":"Bonsdorff E, Jalavisto E (1948) A humoral mechanism in anoxic erythrocytosis. Acta Physiol Scand 16:150\u2013170","journal-title":"Acta Physiol Scand"},{"key":"3799_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1600-0609.2007.00818.x","volume":"78","author":"W Jelkmann","year":"2007","unstructured":"Jelkmann W (2007) Erythropoietin after a century of research: younger than ever. Eur J Haematol 78:183\u2013205","journal-title":"Eur J Haematol"},{"key":"3799_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/179633a0","volume":"179","author":"LO Jacobson","year":"1957","unstructured":"Jacobson LO, Goldwasser E, Fried W, Plzak L (1957) Role of the kidney in erythropoiesis. Nature 179:633\u2013634","journal-title":"Nature"},{"key":"3799_CR14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1172\/JCI113363","volume":"81","author":"C Lacombe","year":"1988","unstructured":"Lacombe C, Da Silva JL, Bruneval P, Fournier JG, Wendling F, Casadevall N, Camilleri JP, Bariety J, Varet B, Tambourin P (1988) Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 81:620\u2013623","journal-title":"J Clin Invest"},{"key":"3799_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-1-4613-0623-8_8","volume":"271","author":"C Lacombe","year":"1989","unstructured":"Lacombe C, Da Silva JL, Bruneval P, Salzmann JL, Casadevall N, Camilleri JP, Bariety J, Varet B, Tambourin P (1989) Cellular localization of erythropoietin gene transcription. Adv Exp Med Biol 271:69\u201374","journal-title":"Adv Exp Med Biol"},{"key":"3799_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1182\/blood.V40.5.671.671","volume":"40","author":"W Fried","year":"1972","unstructured":"Fried W (1972) The liver as a source of extrarenal erythropoietin production. Blood 40:671\u2013677","journal-title":"Blood"},{"key":"3799_CR17","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1016\/S0021-9258(19)63387-9","volume":"252","author":"T Miyake","year":"1977","unstructured":"Miyake T, Kung CK, Goldwasser E (1977) Purification of human erythropoietin. J Biol Chem 252:5558\u20135564","journal-title":"J Biol Chem"},{"key":"3799_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/313806a0","volume":"313","author":"K Jacobs","year":"1985","unstructured":"Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, Hewick R, Fritsch EF, Kawakita M, Shimizu T, Miyake T (1985) Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313:806\u2013810","journal-title":"Nature"},{"key":"3799_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0171-2985(86)80101-2","volume":"172","author":"JC Egrie","year":"1986","unstructured":"Egrie JC, Strickland TW, Lane J, Aoki K, Cohen AM, Smalling R, Trail G, Lin FK, Browne JK, Hines DK (1986) Characterization and biological effects of recombinant human erythropoietin. Immunobiology 172:213\u2013224","journal-title":"Immunobiology"},{"key":"3799_CR20","doi-asserted-by":"publisher","first-page":"7580","DOI":"10.1073\/pnas.82.22.7580","volume":"82","author":"FK Lin","year":"1985","unstructured":"Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 82:7580\u20137584","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3799_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM198701083160203","volume":"316","author":"JW Eschbach","year":"1987","unstructured":"Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New Eng J Med 316:73\u201378","journal-title":"New Eng J Med"},{"key":"3799_CR22","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1182\/blood.V77.12.2583.2583","volume":"77","author":"VC Broudy","year":"1991","unstructured":"Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T (1991) Erythropoietin receptor characteristics on primary human erythroid cells. Blood 77:2583\u20132590","journal-title":"Blood"},{"key":"3799_CR23","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2310\/JIM.0b013e31820fb28c","volume":"59","author":"SS Watowich","year":"2011","unstructured":"Watowich SS (2011) The erythropoietin receptor: molecular structure and hematopoietic signaling pathways. J Investig Med 59:1067\u20131072","journal-title":"J Investig Med"},{"key":"3799_CR24","first-page":"671","volume":"46","author":"LF Plzak","year":"1955","unstructured":"Plzak LF, Fried W, Jacobson LO, Bethard WF (1955) Demonstration of stimulation of erythropoiesis by plasma from anemic rats using Fe59. J Lab Clin Med 46:671\u2013678","journal-title":"J Lab Clin Med"},{"key":"3799_CR25","first-page":"751","volume":"35","author":"PM Cotes","year":"1966","unstructured":"Cotes PM, Bangham DR (1966) The international reference preparation of erythropoietin. Bull World Health Organ 35:751\u2013760","journal-title":"Bull World Health Organ"},{"key":"3799_CR26","first-page":"99","volume":"47","author":"L Annable","year":"1972","unstructured":"Annable L, Cotes PM, Mussett MV (1972) The second international reference preparation of erythropoietin, human, urinary, for bioassay. Bull World Health Organ 47:99\u2013112","journal-title":"Bull World Health Organ"},{"key":"3799_CR27","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1677\/joe.0.1340459","volume":"134","author":"PL Storring","year":"1992","unstructured":"Storring PL, Gaines Das RE (1992) The International Standard for Recombinant DNA-derived Erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J Endocrinol 134:459\u2013484","journal-title":"J Endocrinol"},{"key":"3799_CR28","first-page":"405","volume":"5","author":"JF Garcia","year":"1979","unstructured":"Garcia JF, Sherwood J, Goldwasser E (1979) Radioimmunoassay of erythropoietin. Blood Cells 5:405\u2013419","journal-title":"Blood Cells"},{"key":"3799_CR29","unstructured":"abcam. Human Erythropoietin ELISA Kit. http:\/\/www.abcam.com\/human-erythropoietin-elisa-kit-epo-ab119522.html . Accessed 15 March 2018."},{"key":"3799_CR30","unstructured":"BioVendor. Erythropoietin Human ELISA. https:\/\/www.biovendor.com\/erythropoietin-human-elisa . Accessed 15 March 2018."},{"key":"3799_CR31","unstructured":"Stemcell Technologies. Erythropoietin (EPO) ELISA Kit. https:\/\/www.stemcell.com\/erythropoietin-epo-elisa-kit.html . Accessed 15 March 2018."},{"key":"3799_CR32","unstructured":"ThermoFisher. Epo Human ELISA Kit, Short incubation. https:\/\/www.thermofisher.com\/order\/catalog\/product\/BMS2035 . Accessed 15 March 2018."},{"key":"3799_CR33","unstructured":"R&D Systems. Human Erythropoietin Quantikine IVD ELISA Kit. https:\/\/www.rndsystems.com\/products\/human-erythropoietin-quantikine-ivd-elisa-kit_dep00 . Accessed 15 March 2018."},{"key":"3799_CR34","doi-asserted-by":"publisher","first-page":"e0125215","DOI":"10.1371\/journal.pone.0125215","volume":"10","author":"N Grote Beverborg","year":"2015","unstructured":"Grote Beverborg N, Verweij N, Klip IT, van der Wal HH, Voors AA, van Veldhuisen DJ, Gansevoort RT, Bakker SJ, van der Harst P, Pl v d M (2015) Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. PloS One 10:e0125215","journal-title":"PloS One"},{"key":"3799_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12185-013-1485-7","volume":"99","author":"K Nakazaki","year":"2014","unstructured":"Nakazaki K, Nannya Y, Kurokawa M (2014) Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia. Int J Hematol 99:53\u201356","journal-title":"Int J Hematol"},{"key":"3799_CR36","first-page":"111","volume":"4","author":"P Pasqualetti","year":"2000","unstructured":"Pasqualetti P, Collacciani A, Casale R (2000) Circadian rhythm of serum erythropoietin in myelodysplastic syndromes. Eur Rev Med Pharmacol Sci 4:111\u2013115","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3799_CR37","first-page":"3671","volume":"96","author":"BD Cheson","year":"2000","unstructured":"Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, L\u00f6wenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671\u20133674","journal-title":"Blood"},{"key":"3799_CR38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419\u2013425","journal-title":"Blood"},{"key":"3799_CR39","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1046\/j.1365-2141.1997.4013211.x","volume":"99","author":"E Hellstrom-Lindberg","year":"1997","unstructured":"Hellstrom-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Ost A, Greenberg P (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99:344\u2013351","journal-title":"Br J Haematol"},{"key":"3799_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood.V92.1.68.413k23_68_75","volume":"92","author":"E Hellstrom-Lindberg","year":"1998","unstructured":"Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, L\u00f6fvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, Oberg G, Osterborg A, Ost A (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68\u201375","journal-title":"Blood"},{"key":"3799_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1034\/j.1600-0609.2002.01530.x","volume":"68","author":"J Wallvik","year":"2002","unstructured":"Wallvik J, Stenke L, Bernell P, Nordahl G, Hippe E, Hast R (2002) Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol 68:180\u2013185","journal-title":"Eur J Haematol"},{"key":"3799_CR42","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","volume":"120","author":"E Hellstrom-Lindberg","year":"2003","unstructured":"Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, L\u00f6fvenberg E, Oberg G, Porwit-MacDonald A, R\u00e5dlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120:1037\u20131046","journal-title":"Br J Haematol"},{"key":"3799_CR43","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1365-2141.2004.05288.x","volume":"128","author":"P Musto","year":"2005","unstructured":"Musto P, Lanza F, Balleari E, Grossi A, Falcone A, Sanpaolo G, Bodenizza C, Scalzulli PR, La Sala A, Campioni D, Ghio R, Cascavilla N, Carella AM (2005) Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128:204\u2013209","journal-title":"Br J Haematol"},{"key":"3799_CR44","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1093\/annonc\/mdi400","volume":"16","author":"R Stasi","year":"2005","unstructured":"Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S (2005) Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 16:1921\u20131927","journal-title":"Ann Oncol"},{"key":"3799_CR45","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2141.2006.06070.x","volume":"133","author":"L Mannone","year":"2006","unstructured":"Mannone L, Gardin C, Quarre MC, Bernard JF, Vassilieff D, Ades L, Park S, Vaultier S, Hamza F, Beyne-rauzy MO, Cheze S, Giraudier S, Agape P, Legros L, Voillat L, Dreyfus F, Fenaux P (2006) High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 133:513\u2013519","journal-title":"Br J Haematol"},{"key":"3799_CR46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2141.2008.07181.x","volume":"142","author":"J Gabrilove","year":"2008","unstructured":"Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, Dreiling L (2008) Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 142:379\u2013393","journal-title":"Br J Haematol"},{"key":"3799_CR47","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","volume":"111","author":"S Park","year":"2008","unstructured":"Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, Cheze S, Mah\u00e9 B, Ferrant A, Ravoet C, Escoffre-Barbe M, Ad\u00e8s L, Vey N, Aljassem L, Stamatoullas A, Mannone L, Dombret H, Bourgeois K, Greenberg P, Fenaux P, Dreyfus F (2008) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111:574\u2013582","journal-title":"Blood"},{"key":"3799_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ajh.21316","volume":"84","author":"J Gotlib","year":"2009","unstructured":"Gotlib J, Lavori P, Quesada S, Stein RS, Shahnia S, Greenberg PL (2009) A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol 84:15\u201320","journal-title":"Am J Hematol"},{"key":"3799_CR49","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","volume":"114","author":"PL Greenberg","year":"2009","unstructured":"Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, van der Jagt R, Houston J, Thomas ML, Cella D, Rowe JM (2009) Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 114:2393\u20132400","journal-title":"Blood"},{"key":"3799_CR50","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.3324\/haematol.2010.024349","volume":"95","author":"E Frisan","year":"2010","unstructured":"Frisan E, Pawlikowska P, Pierre-Eugene C, Viallon V, Gibault L, Park S, Mayeux P, Dreyfus F, Porteu F, Fontenay M (2010) p-ERK1\/2 is a predictive factor of response to erythropoiesis-stimulating agents in low\/int-1 myelodysplastic syndromes. Haematologica 95:1964\u20131968","journal-title":"Haematologica"},{"key":"3799_CR51","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1182\/blood-2009-08-239749","volume":"115","author":"TM Westers","year":"2010","unstructured":"Westers TM, Alhan C, Chamuleau ME, van der Vorst MJ, Eeltink C, Ossenkoppele GJ, van de Loosdrecht A (2010) Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 115:1779\u20131784","journal-title":"Blood"},{"key":"3799_CR52","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.leukres.2010.05.030","volume":"34","author":"S Park","year":"2010","unstructured":"Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-Rauzy O, Coiteux V, Vey N, Ravoet C, Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP, Fenaux P, Dreyfus F (2010) Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res 34:1430\u20131436","journal-title":"Leuk Res"},{"key":"3799_CR53","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1185\/03007995.2011.561834","volume":"27","author":"A Villegas","year":"2011","unstructured":"Villegas A, Arrizabalaga B, Fernandez-Lago C, Castro M, Mayans JR, Gonzalez-Porras JR, Duarte RF, Remacha AF, Lu\u00f1o E, Gasquet JA (2011) Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin 27:951\u2013960","journal-title":"Curr Med Res Opin"},{"key":"3799_CR54","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00277-013-1686-4","volume":"92","author":"C Kelaidi","year":"2013","unstructured":"Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Ad\u00e8s L, Pillard F, Lamberto C, Charniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury MP, Legros L, Cheze S, Testu A, Gyan E, B\u00e9n\u00e9 MC, Rose C, Dreyfus F, Fenaux P (2013a) High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol 92:621\u2013631","journal-title":"Ann Hematol"},{"key":"3799_CR55","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/leu.2013.16","volume":"27","author":"C Kelaidi","year":"2013","unstructured":"Kelaidi C, Park S, Sapena R, Beyne-Rauzy O, Coiteux V, Vey N, Stamatoullas A, Choufi B, Delaunay J, Gourin MP, Cheze S, Ravoet C, Ferrant A, Escoffre-Barbe M, Aljassem L, Raffoux E, Itzykson R, Ad\u00e8s L, Dreyfus F, Fenaux P (2013b) Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia 27:1283\u20131290","journal-title":"Leukemia"},{"key":"3799_CR56","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2013-07-512442","volume":"122","author":"V Santini","year":"2013","unstructured":"Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Ades L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Am\u00e9 S, Fenaux P, Germing U, Dreyfus F, Park S (2013) Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? Blood 122:2286\u20132288","journal-title":"Blood"},{"key":"3799_CR57","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s12185-013-1305-0","volume":"97","author":"A Molteni","year":"2013","unstructured":"Molteni A, Riva M, Greco R, Nichelatti M, Ravano E, Marbello L, Nosari A, Morra E (2013) Verifying Hellstrom-Lindberg score as predictive tool for response to erythropoietin therapy according to the \u201cInternational Working Group\u201d criteria, in anemic patients affected by myelodysplastic syndrome: a monocentric experience. Int J Hematol 97:472\u2013479","journal-title":"Int J Hematol"},{"key":"3799_CR58","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12185-015-1862-5","volume":"102","author":"JH Jang","year":"2015","unstructured":"Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K (2015) A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. Int J Hematol 102:401\u2013412","journal-title":"Int J Hematol"},{"issue":"101","key":"3799_CR59","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.3324\/haematol.2016.142695","volume":"2016","author":"O Kosmider","year":"2016","unstructured":"Kosmider O, Passet M, Santini V, Platzbecker U, Andrieu V, Zini G, Beyne-Rauzy O, Guerci A, Masala E, Balleari E, Bulycheva E, Dreyfus F, Fenaux P, Fontenay M, Park S (2016) Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes? Haematologica 2016(101):e280\u2013e283","journal-title":"Haematologica"},{"key":"3799_CR60","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/ajh.24842","volume":"92","author":"R Buckstein","year":"2017","unstructured":"Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Cris\u00e0 E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F (2017) ITACA: a new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems. Am J Hematol 92:1037\u20131046","journal-title":"Am J Hematol"},{"key":"3799_CR61","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s00277-017-3137-0","volume":"96","author":"BL Houston","year":"2017","unstructured":"Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KWL, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Elemary M, Delage R, Mamedov A, Buckstein R (2017) A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry. Ann Hematol 96:2025\u20132029","journal-title":"Ann Hematol"},{"key":"3799_CR62","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1200\/JCO.2016.71.3271","volume":"35","author":"S Park","year":"2017","unstructured":"Park S, Hamel HF, Toma A, Kelaidi C, Thepot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, G\u00f6tze K, M\u00fcller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P (2017) Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents. J Clin Oncol 35:1591\u20131597","journal-title":"J Clin Oncol"},{"key":"3799_CR63","first-page":"1058","volume":"84","author":"AF Remacha","year":"1999","unstructured":"Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julia A, Fern\u00e1ndez Fuertes I, Gonz\u00e1lez FA, Font L, Junc\u00e0 J, del Arco A, Malcorra JJ, Equiza EP, de Mendiguren BP, Romero M (1999) Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica 84:1058\u20131064","journal-title":"Haematologica"},{"key":"3799_CR64","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1182\/blood-2003-06-2124","volume":"103","author":"RB Howe","year":"2004","unstructured":"Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E (2004) The WHO classification of MDS does make a difference. Blood 103:3265\u20133270","journal-title":"Blood"},{"key":"3799_CR65","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1365-2257.1997.tb00007.x","volume":"19","author":"R Stasi","year":"1997","unstructured":"Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, La Presa M, Bianchi M, Parma A, Pagano A (1997) Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin Lab Haematol 19:197\u2013201","journal-title":"Clin Lab Haematol"},{"key":"3799_CR66","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/bjh.14116","volume":"174","author":"S Park","year":"2016","unstructured":"Park S, Fenaux P, Greenberg P, Mehta B, Callaghan F, Kim C, Tomita D, Xu H (2016) Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. Br J Haematol 174:730\u2013747","journal-title":"Br J Haematol"},{"key":"3799_CR67","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.3109\/10428194.2014.891027","volume":"55","author":"AT Gerds","year":"2014","unstructured":"Gerds AT, Sekeres MA (2014) Initial transfusion frequency and survival in myelodysplastic syndromes: hopping onto a fast train to nowhere. Leuk Lymphoma 55:2221\u20132222","journal-title":"Leuk Lymphoma"},{"key":"3799_CR68","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1182\/asheducation-2016.1.462","volume":"2016","author":"V Santini","year":"2016","unstructured":"Santini V (2016) Treatment of low-risk myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2016:462\u2013469","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3799_CR69","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","volume":"34","author":"V Santini","year":"2016","unstructured":"Santini V, Almeida A, Giagounidis A, Gropper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Ca\u00f1izo C, Gattermann N, Ozawa K, Risue\u00f1o A, MacBeth KJ, Zhong J, S\u00e9guy F, Hoenekopp A, Beach CL, Fenaux P (2016) Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol 34:2988\u20132996","journal-title":"J Clin Oncol"},{"key":"3799_CR70","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/leu.2015.296","volume":"30","author":"A Toma","year":"2016","unstructured":"Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F (2016) Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia 30:897\u2013905","journal-title":"Leukemia"},{"key":"3799_CR71","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2012-03-415661","volume":"120","author":"RS Komrokji","year":"2012","unstructured":"Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R, Saba HI, List AF (2012) Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood 120:3419\u20133424","journal-title":"Blood"},{"key":"3799_CR72","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","volume":"18","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Germing U, Gotze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A (2017) Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicenter, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol 18:1338\u20131347","journal-title":"Lancet Oncol"},{"key":"3799_CR73","doi-asserted-by":"publisher","first-page":"720","DOI":"10.20344\/amp.6518","volume":"28","author":"E Cortesao","year":"2015","unstructured":"Cortesao E, Tenreiro R, Ramos S, Pereira M, Cesar P, Carda JP, Gomes M, Rito L, Magalh\u00e3es E, Gon\u00e7alves AC, Silva NC, Geraldes C, Pereira A, Ribeiro L, Nascimento Costa JM, Ribeiro AB (2015) Serum erythropoietin as prognostic marker in myelodysplastic syndromes. Acta Med Port 28:720\u2013725","journal-title":"Acta Med Port"},{"key":"3799_CR74","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1182\/blood.V89.12.4248","volume":"89","author":"M Cazzola","year":"1997","unstructured":"Cazzola M, Mercuriali F, Brugnara C (1997) Use of recombinant human erythropoietin outside the setting of uremia. Blood 89:4248\u20134267","journal-title":"Blood"},{"key":"3799_CR75","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12185-014-1699-3","volume":"101","author":"T Suzuki","year":"2015","unstructured":"Suzuki T, Oh I, Ohmine K, Meguro A, Mori M, Fujiwara S, Yamamoto C, Nagai T, Ozawa K (2015) Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes. Int J Hematol 101:32\u201336","journal-title":"Int J Hematol"},{"key":"3799_CR76","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1158\/1078-0432.CCR-11-0686","volume":"18","author":"E Spinelli","year":"2012","unstructured":"Spinelli E, Caporale R, Buchi F, Masala E, Gozzini A, Sanna A, Sassolini F, Valencia A, Bosi A, Santini V (2012) Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. Clin Can Res 18:3079\u20133089","journal-title":"Clin Can Res"},{"key":"3799_CR77","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1182\/blood.V99.5.1594","volume":"99","author":"YE Claessens","year":"2002","unstructured":"Claessens YE, Bouscary D, Dunport JM, Picard F, Melle J, Gisselbrecht S, Lacombe C, Dreyfus F, Mayeux P, Fontenay-Roupie M (2002) In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 99:1594\u20131601","journal-title":"Blood"},{"key":"3799_CR78","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"L Malcovati","year":"2013","unstructured":"Malcovati L, Hellstr\u00f6m-Lindberg E, Bowen D, Ad\u00e8s L, Cermak J, del Ca\u00f1izo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122:2943\u20132964","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1007\/s00277-019-03874-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03799-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03799-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03799-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T05:48:46Z","timestamp":1611640126000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03799-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["3799"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03799-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"16 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published without an Open Access but due to the authors final decision to opt for Open Choice this correction was created.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.P. received research support from Celgene Corporation, Janssen, Pfizer, and Roche. C.K., M.M., N.C., and A.T.G. declare that they have no competing interests. U.P. received research support from Amgen and Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}